Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report.

International journal of colorectal disease - 1 Jun 2016

Boidot Romain, Chevrier Sandy, Julie Vincent, Ladoire Sylvain, Ghiringhelli Francois

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Colorectal Neoplasms
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to HRAS gene

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 26561417
DOI: 10.1007/s00384-015-2448-7

Genes

EGFR
HRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case report.PMID 26561417Read ↗

Rare EGFR exon 20 S768I mutation predicts resistance to targeted therapy: a report of two cases.Semantic proximity Read ↗

Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.Semantic proximity Read ↗

Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.Semantic proximity Read ↗

First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation.Semantic proximity Read ↗

First case of A859T epidermal growth factor receptor mutation responding to erlotinib.Semantic proximity Read ↗

Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancerSemantic proximity Read ↗

Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation.Semantic proximity Read ↗

Response to (K)RASG12C and EGFR Inhibition in a Patient With NRASG12C-Mutated Rectal Cancer.Semantic proximity Read ↗

Recurring G12S mutation of HRAS in a Chinese child with Costello syndrome with high alkaline phosphatase level.Semantic proximity Read ↗

A case of gene mutation responsible for GIST drug resistance.Semantic proximity Read ↗

A novel Q562X mutation identified in the hMLH1 gene in a Slovenian patient with hereditary nonpolyposis colorectal cancer.Semantic proximity Read ↗

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.